A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

NCT07055607 · Enrolling by invitation

Last updated 2026-05-28

This study will observe adults with obesity over two years to track changes in body weight while using Wegovy in real-world medical settings.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 1,250 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-05 · est. completion 2028-08

Where 30 sites · Spain, Switzerland, United Kingdom

What this study is testing ClinicalTrials.gov NCT07055607 ↗

Description as written by the study sponsor.

This observational study will explore how Wegovy® (Semaglutide) is used in everyday situations, how it might affect things like weight, body mass index (BMI) and waist circumference, and what kind of impact it could have on overall quality of life. The overall purpose of this study is to understand how Wegovy impacts weight when used as part of regular medical care. Participants will be treated with Wegovy as prescribed to the participant by their doctor, in accordance with normal clinical practice. The study will last for about two years.

Treatments tested

Semaglutide also known as Wegovy® Drug

Participants will be treated with commercially available Wegovy according to routine clinical practice and is purely at the discretion of the treating physician. Only individuals receiving Wegovy reimbursed by the healthcare system in their respective countries are included in the study.

Main thing measured	Absolute change in body weight (kilograms [kg])
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07055607 ↗